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aspirin withdrawal in vivo, our study was conducted in patients with low-risk cardiovascular disease
who can stop aspirin administration following the guidelines stipulated by the American College of Chest
Physicians. The time it takes for platelet activity to normalize and the diagnostic accuracy of testing
methods were assessed for a residual antiplatelet activity with multiple electrode aggregometry. Our
study included patients with clinically indicated hypertension preparing for a dental extraction
procedure.
Materials and methods: A total of 212 patients not taking aspirin (control group) and 248 patients with
hypertension receiving long-time aspirin treatment at a 100-mg daily dose were prospectively included
in the study, which involved stopping aspirin intake before dental extraction. The residual platelet
activity and dental bleeding in patients who stopped aspirin intake were analyzed and compared with
those of the control group. In addition, platelet reactivity recovery time and bleeding risk in patients who
stopped taking aspirin every 24 hours for 0 to 5 days (0–143 hours) before dental extraction was also
assessed.
Results: Platelet reactivity normalized 96 hours after aspirin withdrawal. The cut-off value of 49 arbitrary
units in the arachidonic acid platelet aggregation test excluded the effect of aspirin with 91% sensitivity
and 66% speciﬁcity. AUC showed 0.86 (P o 0.001) diagnostic accuracy. The immediate bleeding
complications in all treatment groups were similar to those seen in the control group and were
successfully managed with local hemostatic measures.
Conclusions: The antiplatelet effects of aspirin disappeared 96 hours after aspirin withdrawal in our
study, and dental extractions may be safely performed in this period when appropriate local hemostatic
measures are taken. Based on these results, a shorter aspirin intake cessation period may be allowable in
complex dental procedures and surgery for which a longer aspirin intake cessation period (7–10 days) is
recommended based on the American College of Chest Physicians guidelines.
& 2014. The Authors. Published by Elsevier Inc. All rights reserved. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Platelets play a pivotal role in the pathophysiology of ischemic
complications of atherosclerotic cardiovascular disease. Aspiriner Inc. All rights reserved. This is a
, PhD, Cardiovascular Center,
n 301-725, Republic of Korea.acts on platelets by acetylating the cyclooxygenase enzyme at
position serine 529, resulting in reduced formation of cyclic
endoperoxides (prostaglandin G2 and prostaglandin H2) and
thromboxane from arachidonic acid. Aspirin is an oral antiplatelet
drug commonly used to reduce adverse clinical events across a
wide spectrum of patients with atherothrombotic disease.1–3
An increasing number of patients undergoing dental proce-
dures or surgery ingest aspirin. The American College of Chest
Physicians (ACCP) recommends that patients scheduled forn open access article under the CC BY-NC-ND license
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throughout the time of coronary artery bypass grafting despite
published reports of increased risk of perioperative bleeding.4,5
Preoperative aspirin administration increases blood loss during
bleeding-sensitive operations.6–8 Thus, ACCP guidelines suggest
that patients about to undergo noncardiac surgery who are at low
risk for cardiac disease stop aspirin intake 7 to 10 days before
surgery.
The optimal dental management in patients receiving long-
term aspirin treatment has yet to be clearly deﬁned. Antiplatelet
discontinuation increases the risk of thrombotic complications,
whereas uninterrupted antiplatelet therapy is assumed to increase
risk of bleeding after dental procedures. The effect of aspirin on the
amount of bleeding that occurs during tooth extraction procedures
is controversial, and the perioperative guidelines recommend that
aspirin administration should not be altered for such procedures.
Dental extraction may be safely performed in patients receiving
single or dual antiplatelet therapy when appropriate local hemo-
static measures are taken.9
For patients preparing to undergo a dental procedure, detection
of the degree of residual-aspirin-induced suppression of platelet
activity in accordance with the duration of aspirin withdrawal
could not only result in appropriate postponement of complex or
bleeding-sensitive dental procedure but also prevent the unneces-
sary postponement of a simple dental procedure.
Multiple electrode aggregometry (MEA) is a newly developed
technique for testing platelet function in whole blood based on
classic whole-blood impedance aggregometry. It has been used to
study the effects of aspirin and clopidogrel on platelet aggrega-
tion.10,11 MEA does not require a specialized coagulation laboratory
and may be useful for point-of-care analysis.12–14 Up to now, no
information has been available regarding the use of MEA for the
determination of the time course of platelet inhibition after the
ingestion of a single 100-mg dose of aspirin.
To determine the platelet reactivity recovery time after aspirin
withdrawal in vivo, our study was conducted among patients with
low-risk cardiovascular disease who can stop aspirin intake
following the ACCP guideline. The residual-aspirin-induced sup-
pression of platelet reactivity with MEA was assessed in patients
who needed to stop aspirin intake before dental extraction. Results
of the time course assessment of the antiplatelet effects and the
bleeding risk after cessation of a single oral dose of 100 mg aspirin
was examined with MEA before dental extraction in patients with
hypertension, which is associated with low risk for ischemic
cardiac disease. The diagnostic value of MEA in the assessment
of residual platelet reactivity after the cessation of aspirin intake
was also determined.Materials and Methods
Study population
All patients older than age 18 years consecutively referred for
dental extractions were prospectively screened from October 2011
to April 2013 at 2 centers. The control group, those who were not
taking aspirin, and the patients who had been taking 100 mg
aspirin and antihypertensive medication daily were included at
each center. These patients were randomly assigned to 6 groups
that were to stop aspirin intake for 0 to 5 days before dental
extraction. Based on the ﬁndings in the aspirin-treated healthy
volunteers in a study conducted by Jámbor et al,15 it was
hypothesized that the platelet function in patients who stopped
aspirin intake before the dental procedure would gradually nor-
malize, with wide interindividual variation on Days 3 and 4
(between 48 and 96 hours) after the ﬁnal ingestion of aspirin.On Day 5 and thereafter (after 96 hours), no detectable aspirin
effect was expected. Thus, our study was designed to assess the
platelet activity recovery time and the bleeding risk in patients
who stopped taking aspirin 0 to 5 days (0–143 hours) before
dental extraction. Our study was conducted according to Good
Clinical Practice and in accordance with the Declaration of Helsinki
and all its subsequent amendments. The ethics committee or
institutional review board of each participating center approved
the protocol, and all study participants gave written informed
consent during enrollment.
Dental procedures
Anterior mandibular and maxillary teeth were extracted under
local anesthetic injection in the buccal and palatal or lingual aspect
of the teeth. Posterior mandibular teeth were extracted under a
combination of inferior alveolar nerve block anesthesia and
anesthesia inﬁltration done buccally and lingually. A solution of
2% lidocaine 1.8 mL with epinephrine 1:80,000 was inﬁltrated into
each extraction site to ensure similar local hemostatic effects of
epinephrine.
Patients were instructed to bite on a pressure pack for 30
minutes after the dental extractions. In patients in whom bleeding
was still present, a piece of oxidized regenerated cellulose gauze
was sutured over the inlet of the postextraction socket (these
sutures were removed on Day 6). The patients then bit on a
pressure pack for 30 minutes for a second time, and were
evaluated before leaving the hospital. All patients were given
appropriate postoperative instructions and were advised to imme-
diately report the occurrence of any hemorrhagic problem. The
patients were interviewed by telephone at the end of the extrac-
tion day, and bleeding complaints were recorded.
Estimation of bleeding after dental procedure
The bleeding complications after dental extraction were classi-
ﬁed according to the time of occurrence as immediate (occurring
during the extraction session at the clinic) or late (occurring any
time thereafter). Prolonged immediate bleeding was deﬁned by
the need to use hemostatic gauze when the blood extended
beyond the tooth socket after 30 minutes of biting on a pressure
pack. Late bleeding complications were deﬁned as clinically sig-
niﬁcant when they extended beyond 12 hours, made the patient
call or return to the dental practitioner or to an emergency
department, resulted in hematoma or ecchymosis within the oral
soft tissues, or required blood transfusion.
Exclusion criteria
Patients were excluded if they had a history of bleeding
diathesis, chronic oral anticoagulation treatment, o30% hematoc-
rit, a o80/nL platelet count, or any known congenital or acquired
hemostasis disorder, with the exception of aspirin-induced platelet
dysfunction. Patients with a history of acute myocardial infarction,
unstable angina, stable angina with coronary artery stenting,
stroke, and concomitant administration of other antiplatelet or
nonopioid anti-inﬂammatory agent were also excluded.
As in previous reports assessing the bleeding risk of multiple
extractions in patients receiving oral anticoagulation who needed
multiple extractions (43 teeth), surgical extractions, extractions
in deferent quadrants, or deciduous teeth were excluded.16
Compliance
To optimize the compliance of patients whose last aspirin intake
doses were documented, face-to-face interviews were conducted.
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pills remaining in the containers were counted. Adherence was
deﬁned by the number of pills taken (dispensed pills – returned
pills) in relation to the theoretical prescribed doses.
Blood sampling and intervention
Blood was sampled from the antecubital vein without stasis
using a 21G butterﬂy needle. The ﬁrst 2 mL blood was discarded.
Blood was then collected in 4.5-mL tubes containing 25 μg/mL
hirudin (Dynabyte, Munich, Germany) as an anticoagulant accord-
ing to the manufacturer’s recommendations. After blood drawing
at baseline, all participants in the control group took 1 tablet of
100 mg aspirin (Aspirin Protect; Bayer, Leverkusen, Germany) in
the presence of a study advisor, followed by extraction of addi-
tional blood samples. The hematocrit, leukocytes, and platelet
count were determined from the EDTA blood samples using an
SF 3000 analyzer (Sysmex Corp, Kobe, Japan).
Platelet aggregation test
Platelet function analysis was performed using the Multiplate
analyzer, a novel whole-blood impedance aggregometry device
(Dynabyte, Munich, Germany). The device has 5 MEA test cells for
parallel testing, and each test cell incorporates 2 independent
sensor units. One unit consists of 2 silver-coated, highly conductive
copper wires. Analysis was based on the platelet adhesion upon
activation, a property that results in aggregation onto the metal
sensor wires in the test cell, thus increasing the electrical impe-
dance between the wires. For measurement, 300 μL preheated
saline (371C) and 300 μL hirudin-anticoagulated whole blood were
placed in the test cell, and the sample was stirred using a Teﬂon
(DuPont Company, Wilmington, Delaware)-coated electromagnetic
stirrer (800 revolutions/min) over a 3-minute incubation period.
Platelet aggregationwas initiated using arachidonic acid (arachidonic acid
platelet aggregation [ASPI] test, 0.5 mM), the reagent supplied by the
manufacturer (Dynabyte, Munich, Germany). Increased impedance due to
the attachment of platelets to the electrodes was continuously measured
for the sensor unit over a period of 6minutes. The datawere transformed
into arbitrary units (AU) and were plotted as 2 separate aggregation
curves versus time.Table I
Baseline characteristics.
Aspirin withdrawal, h
Variable* Control 0-23 24-47
Patients 212 42 40
Age, y 62 (13.4) 64.4 (10.2) 63.4 (11.2)
Male 51 47 49
Weight, kg 61.7 (14.7 58.3 (13.2) 60.3 (15.2
Height, cm 168 (8.1) 167 (8.3) 168 (8.7
Body mass index 25.2 (22.0/29.1) 25.3 (22.3/28.9) 25.7 (23.1/27.9)
Platelet count, n/L 226 (192/280) 228 (189/278) 225 (196/273)
Hematocrit, % 41.1 (36.9/45.7) 40.8 (36.7/45.4) 40.1 (36.5/44.7)
Leucocytes, n/L 6.2 (5.4/8.6) 6.5 (4.4/8.1) 6.1 (4.7/8.0)
Smoking 62 (29.1) 13 (31.2) 12 (29.6)
No. of teeth extracted 325 50 51
Indication for extraction
Periodontitis 155 (47.7) 24 (48.0) 22 (43.1)
Radicular lesion 39 (12.0) 6 (12.0) 8 (15.7)
Severe decay 126 (38.8) 20 (40.0) 21 (41.2)
Other 5 (1.5) 0 (0) 0 (0)
NA ¼ not applicable.
n Data are expressed as mean (SD) or median (25th/75th percentile), according to t
percentage values.
† P value indicates controls versus all of aspirin withdrawal groups.The aggregation measured using MEA was quantiﬁed as the
AUC. The duplicate sensors served as an internal control to reduce
the occurrence of systematic errors. Pearson’s correlation coefﬁ-
cients of the individual data points of the curves as assessed by the
2 electrode pairs and the differences between the AUC values
detected by the sensor unit and the mean AUC were calculated.
When the values were outside the acceptable range (correlation
coefﬁcient o0.98 or difference from the mean curve 420%), the
results were ﬂagged and the measurement was repeated.
The institutional reference range was deﬁned as between the
10th and 90th percentiles of the control group (no aspirin intake)
for each assay. An aspirin effect was excluded if the value was
within the institutional reference ranges, or more precisely, above
the 10th percentile of the control group in the ASPI test. Aspirin
resistance was determined to be present if the measurement value
for the full-aspirin-effect group was within the institutional
reference range.
The variability of measurements was quantiﬁed using the mean
of the SDs of the 3 consecutive measurements with 17 healthy
subjects after 100 mg aspirin intake, and were expressed as
percentages of the mean values (% CV).
Statistical analysis
Statistical analysis was performed using NCSS for Windows
version 2007 (NCSS, Kaysville, Utah). The Kolmogorov-Smirnov test
was used to check for the normal distribution of the continuous
data. The result was expressed as mean (SD) if normally distributed,
and as median (25th, 75th percentile) if not. The categorical vari-
ables were compared using the χ2 test. One-way ANOVA on ranks
was used to detect the differences among the groups. In the case of
signiﬁcant differences in group medians, a post hoc multiple-
comparison procedure versus the control group was applied accord-
ing to Dunn’s method. Categorical data were compared using the z
test. To detect signiﬁcant differences in platelet aggregation as 15.0
AU15 and 80% statistical power (α ¼ 0.05 [20]), the sample size
needed to be at least 29 for each aspirin withdrawal group.
The diagnostic accuracy of the platelet function assays in iden-
tifying aspirin-induced platelet inhibition was calculated using
receiver operating characteristic (ROC) curves. For the generation
of ROC curves, the data of the 1- to 5-day aspirin-intake-skipping48-71 72-95 96-119 120-143 P†
45 44 41 46
62 (13.4) 64 (14.4) 65 (11.4) 67 (14.7) 0.14
51 47 54 52 0.66
61.7 (14.7) 59.4 (15.1) 60.5 (14.9) 57.7 (15.4) 0.63
162 (8.6) 163 (9.1) 160 (9.4) 158 (9.6) 0.52
26.5 (23.4/29.5) 25.2 (22.0/29.1) 25.6 (21.1/29.2) 26.9 (23.0/30.1) 0.12
227 (193/271) 239 (190/274) 226 (192/280) 220 (197/279) 0.13
37.8 (32.9/41.7) 38.3 (35.0/43.7) 39.1 (36.1/44.5) 37.4 (32.0/43.7) 0.23
6.8 (5.2/8.5) 6.2 (5.4/8.6) 6.2 (5.3/8,5) 6.4 (5.5/8.6) 0.70
13 (29.4) 14 (31.6) 11 (27.1) 12 (25.8) 0.09
56 53 51 52
25 (44.6) 24 (45.3) 26 (51.0) 23 (44.2) 0.55
6 (10.7) 5 (9.4) 4 (7.8) 5 (9.6) 0.11
23 (41.1) 24 (45.3) 20 (39.2) 24 (46.2) 0.12
2 (3.6) 0 (0) 1 (2.0) 0 (0) NA
he distribution of the data. Characteristics are expressed as absolute numbers and
Table II
Arachidonic acid platelet aggregation in the ASPI test by multiple electrode aggregometry.
Aspirin withdrawal, h
Group 0-23 24-47 48-71 72-95 96-119 120-143
median (25th/75th percentile)
Control 87.0 (66.0/105.0)
ASPI test 10.0* (6.5/19.0) 16.5* (13.0/22.0) 25.5* (21.0/29.0) 71.0* (57.0/90.0) 80.5† (71.5/91.5) 83.0† (73.0/96.0)
n P o 0.001 versus patients without aspirin intake in control group.
† P 4 0.05 versus patients without aspirin intake in control group.
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under the ROC curve, sensitivity (true positives / [true positives þ
false negatives]), and speciﬁcity (true negatives / [true negatives þ
false positives]) of the assays were calculated. Relative risk (RR)
was deﬁned as the ratio of bleeding incidence between 2 groups,
and a corresponding 95% CI was reported for the comparison of
the bleeding risk between groups. The level of statistical signiﬁ-
cance was set at P o 0.05.Results
A total of 470 patients meeting the inclusion and exclusion
criteria were enrolled in the study. A total of 212 patients were
included in the control group, and 258 patients who were taking
aspirin were randomized into 6 groups according to the set
duration of aspirin intake cessation. The medication adherence of
the patients in our study was analyzed to be 97%, a high adherence
rate according to the medication possession ratio of 80% to 100%.
The patients’ demographic and procedural characteristics were
similar, as shown in Table I. The results were analyzed without
deleting the 2 aspirin-nonresponsive patients, 1 (76 AU) in the 0 to
24 hour group and 1 (56 AU) in the 48 to 76 hour group, following
the institutional reference range.
Residual antiplatelet effects with MEA
Results of the aspirin-induced platelet reactivity in the ASPI test
are presented in Table II and Figure 1. All patients in the control
group after aspirin intake, and patients who had stopped taking
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Figure 1. Platelet function as measured through the ASPI test. The short dashed
lines represent the 10th percentiles of the control group. These values were deﬁned
as the cut-off values for the exclusion of the aspirin (ASA) effect. *P o 0.001 versus
patients before aspirin intake in the control group.platelet activity when compared with the control group. There
were signiﬁcant differences between the platelet aggregation
analyses performed after aspirin withdrawal, 24 to 47 hours after
aspirin withdrawal, 48 to 71 hours after aspirin withdrawal, 72 to
95 hours after aspirin withdrawal, and 96 to 119 hours after aspirin
withdrawal, except 120 to 143 hours after aspirin withdrawal.
Seventy-two hours after aspirin withdrawal, the platelet activity
gradually reached a point near the value of the controls, and there
was no difference after more than 96 hours when compared with
the control group.
Diagnostic value of MEA
Quantifying the diagnostic accuracy of MEA with ROC analysis
in detecting residual aspirin effect showed the AUC was 0.86 (P o
0.001) (Figure 2). An AUC value Z49 AU in the ASPI test indicated
a recovered antiplatelet effect of aspirin with 91% sensitivity and
66% speciﬁcity, as shown in Table III.
The results obtained with MEA were consistent and reprodu-
cible, with 9% assay imprecision values, within the range of
modern laboratory point-of-care testing.
Bleeding risk after each period of aspirin intake discontinuation
One patient (0.5%) had prolonged immediate bleeding in the
control group and there was 1 patient with prolonged bleeding in
each aspirin intake discontinuation group (0–23 hours [2.4%; RR ¼
6.8; 95% CI, 0.6–69.2; P ¼ 0.21], 24–47 hours [2.5%; RR ¼ 7.1; 95%
CI, 0.9–69.4; P ¼ 0.17], and 72–95 hours [2.3%; RR ¼ 6.5; 95%
CI, 0.6–67.4; P ¼ 0.22]). Immediate bleeding occurred in 1 patient in
the control group (0.5%) and there was 1 patient with immediate
bleeding in each aspirin withdrawal group (48–71 hours [2.2%;














Figure 2. Diagnostic value of the multiple electrode aggregometry for the exclu-
sion of aspirin-induced platelet inhibition as determined by the receiver operating
characteristic curves.
Table III
Diagnostic accuracy of multiple electrode aggregometry.
ASPI test, U*
Control group 10th percentile 49
Control group 90th percentile 117
Cutoff 49
Sensitivity, % (95% CI) 91 (86-94)
Speciﬁcity, % (95% CI) 66 (55-71)
AUC ROC (95% CI) 0.86 (0.81–0.88)
P o0.001
ASPI ¼ arachidonic acid platelet aggregation; CI ¼ conﬁdential interval. ROC ¼
receiver operating characteristic.
n Cutoff value of the ASPI test for the exclusion of aspirin-induced platelet
activity, as determined by the 10th or 90th percentiles of the values obtained by the
control group (without aspirin intake) (n ¼ 212), with respective sensitivities and
speciﬁcities of the tests for the exclusion of aspirin-induced platelet activity.
Diagnostic values are characterized by the AUC ROC.
J. Lee et al. / Current Therapeutic Research 76 (2014) 26–313095% CI, 0.7–68.1; P ¼ 0.2], and 120–143 hours [2.2%; RR ¼ 6.2; 95%
CI, 0.5–65.6; P ¼ 0.26]). All cases of immediate bleeding were
successfully treated with hemostatic gauze and suturing after dental
extraction. Patients with immediate bleeding did not signiﬁcantly
differ in gender, age, and number or type of extracted teeth across
the different treatment groups. None of the controls or patients who
stopped aspirin intake for 1 to 5 days developed any late hemor-
rhagic complication.Discussion
The main ﬁnding of our study is that aspirin-induced platelet
aggregation in South Korean patients gradually increased 72 hours
after cessation of aspirin intake and returned to the baseline values
96 hours after the cessation of aspirin intake before dental
extraction. All the immediate bleeding complications in all the
treatment groups were similar to those in the patients without
aspirin intake. The diagnostic accuracy of platelet function assay
with MEA showed the area under the ROC curves as 0.86 for the
ASPI test, and 91% and 66% sensitivity and speciﬁcity, respectively.
This indicates the usefulness of the method in assessing aspirin-
induced platelet activity in patients with low cardiovascular risk
before dental extraction. The ASPI test was found to have a degree
of diagnostic accuracy similar to the results obtained by Jámbor
et al15 that involved aspirin-withdrawn patients preparing for
surgery in Europe. Their study showed the area under the ROC
curves as 0.81 for the ASPI test, and the sensitivity and speciﬁcity
as 88% and 71%, respectively, in preoperative patients.
For the choice of aspirin dose, it has been determined that
high-dose aspirin (500–1500 mg daily) is no more effective than
medium-dose aspirin (160–325 mg daily) or low-dose aspirin (75–
150 mg daily) for long-term use.17 A dose of 100 mg daily was
selected in our study because it corresponds to the typical dose of
aspirin ingested as long-term therapy for the primary and secon-
dary prevention of cardiovascular disease in patients with low
cardiovascular risk factors.18 Aspirin caused near-complete inhib-
ition of aspirin-induced platelet aggregation with the ASPI test, as
shown in this study.19,20 The incidence of aspirin nonresponse was
reported to be 5% to 50%, with remarkably different values with
different platelet function tests.21–23 In our study, aspirin resist-
ance was detected in 10% of patients using MEA.
In a recent study involving healthy volunteers and patients with
coronary artery disease, the comparison of light transmission aggreg-
ometry, Platelet Function Analyzer (PFA-100) with Collagen-Epinephr-
ine (COL-EPI) (Dade-Behring, Marburg, Germany), ASPI test, and
VerifyNow (Accumetrics Inc, San Diego, CA) aspirin assay, revealed
that MEA is the most sensitive platelet function assay for aspirin.24Some studies linked MEA data to bleeding12,25 or thrombotic
outcomes.26 A very recent investigation of 100 patients under-
going cardiac surgery suggested that the preoperative ASPI test in
MEA may be a more sensitive predictor of platelet transfusion than
patient self-reporting on aspirin intake.12
Within 72 hours after aspirin intake, more than 80% suppression
of aspirin-induced platelet aggregation was observed in all patients.
The platelet function was gradually normalized 72 hours after drug
withdrawal. This suppressionwas consistent with the results reported
for MEA during long-term aspirin treatment.11 The antiplatelet effect
time course of aspirin assessed using MEA in our study was in
accordance with the results obtained using other monitoring techni-
ques, such as thromboxane B2 production27 or PFA-100,28 considering
that the administered doses in these studies were in fact lower.
Results of our study suggest an important clinical implication in
deciding the appropriate duration of aspirin cessation before
dental extractions without postponing the procedures. Although
ACCP recommends 7- to 10-day aspirin intake cessation before
surgery in patients with low cardiovascular risk, the results of our
study suggest that aspirin intake cessation not longer than 96
hours can be adequate.
The recommendation to stop aspirin intake for 7 to 10 days is
based only on the concern for the mature platelets during
exposure to aspirin. There are some mechanisms that may mod-
ulate the antiplatelet effects in the presence of aspirin and after
aspirin cessation. First, immature platelets, which are reticulated
and larger, have less attenuated and more elevated platelet activity
than mature platelets in the presence of aspirin. Moreover, the
inhibition of human megakaryocyte cyclooxygenase with low
doses of aspirin is incomplete, and megakaryocyte cyclooxygenase
seems to recover within 12 hours after aspirin ingestion.29,30
Second, interruption of the platelet function by aspirin results in
the production of new platelets, presumably through the action of
a feedback system controlling thrombocytopoiesis.31 With the
newly formed platelets from the bone marrow in the absence of
aspirin, these mechanisms may affect the platelet activity recovery
time faster than the life span of the mature platelets.
Study limitations
This study has some limitations. First, it was not designated as
an in vivo study. It could not be determined if low or high platelet
reactivity as determined by the ASPI test actually results in
increased prothromboembolic events. Although platelet reactivity
is a well-validated predictor of the clinical outcomes of thrombotic
ischemic heart disease, large-scale and long-term trials powered
for clinical outcomes will be necessary. Second, the results of our
study are based on measurements using only MEA, but various
studies reported that MEA measurements correlate with light
transmission aggregometry13,14 and ﬂow cytometry.32 Finally,
biochemical measurement to verify aspirin compliance, such as
urinary thromboxane level, was not designated. Instead, standard
pill count was used to assess adherence.Conclusions
The antiplatelet effects of aspirin can be expected within 96
hours after the ﬁnal ingestion of aspirin. Similar bleeding compli-
cations occurred compared with the control group within such
period. The platelet function generally recovers if the aspirin
cessation period exceeds 96 hours. With these results, a shorter
aspirin intake cessation period may be needed in complex dental
procedures and surgery for which a longer aspirin intake cessation
(7–10 days) is recommended by the ACCP guidelines. The ASPI test
might be the preferred diagnostic method for determining the
J. Lee et al. / Current Therapeutic Research 76 (2014) 26–31 31residual effects in patients who need aspirin intake cessation for a
dental procedure or surgery.Acknowledgments
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